Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract
- To measure the change in levels of plasma estrone (E1), estradiol, E1-conjugates, and
E1-sulfates in postmenopausal women after 6 weeks of daily ingestion of 94 grams of
freeze-dried table grape powder.
- To conduct bioavailability research on the freeze-dried table grape powder in humans
through the analysis of participants' blood and urine samples.
OUTLINE: Participants receive oral freeze-dried table grape powder once daily on days 1-42
in addition to their usual diet. Treatment continues in the absence of toxicity.
Participants undergo blood sample collection at baseline, periodically after the first dose,
and on the last day of the study for pharmacokinetic and bioavailability analysis. Samples
are examined by mass spectrometry to measure plasma levels of estrone (E1), estradiol,
E1-conjugates, E1-sulfates, testosterone, and androstenedione. Participants also undergo
spot urine collection and weight and height measurement periodically during study.
Participants complete food diaries on days 1-3, 21-23, and 40-42 to assess their intake of
grapes, grape juice, and red wine and to examine the constancy of their caloric intake over
the course of the study.
Observational Model: Case Control, Time Perspective: Prospective
Serum levels of plasma estrone (E1), estradiol, E1-conjugates, and E1-sulfates
Janet E. Olson, PhD
United States: Federal Government
|Mayo Clinic||Rochester, Minnesota 55905|